about
Recent Advances in Dipeptidyl-Peptidase-4 Inhibition Therapy: Lessons from the Bench and Clinical TrialsThe addition of vildagliptin to metformin prevents the elevation of interleukin 1ß in patients with type 2 diabetes and coronary artery disease: a prospective, randomized, open-label study.Pleiotropic effects of the dipeptidylpeptidase-4 inhibitors on the cardiovascular systemAcute myocardial infarction associated to DPP-4 inhibitorsEmerging gliptins for type 2 diabetes.GLP-1 receptor agonists vs. DPP-4 inhibitors for type 2 diabetes: is one approach more successful or preferable than the other?Vildagliptin in addition to metformin improves retinal blood flow and erythrocyte deformability in patients with type 2 diabetes mellitus - results from an exploratory study.Cardiovascular Outcomes of Sitagliptin in Type 2 Diabetic Patients with Acute Myocardial Infarction, a Population-Based Cohort Study in TaiwanGlucose control and cardiovascular outcomes: reorienting approach.Pleiotropic effects of sitagliptin in the treatment of type 2 diabetes mellitus patients.Choosing between GLP-1 Receptor Agonists and DPP-4 Inhibitors: A Pharmacological Perspective.The effects of dipeptidyl peptidase-4 inhibitors on cardiovascular disease risks in type 2 diabetes mellitus.Dipeptidylpeptidase inhibition is associated with improvement in blood pressure and diastolic function in insulin-resistant male Zucker obese ratsDipeptidyl peptidase-4 inhibition with linagliptin prevents western diet-induced vascular abnormalities in female mice.Dipeptidyl peptidase-4 inhibitors in type 2 diabetes therapy--focus on alogliptin.Cardiovascular Safety of Incretin-Based Therapies in Type 2 Diabetes: Systematic Review of Integrated Analyses and Randomized Controlled Trials.Use of dipeptidyl peptidase-4 inhibitors for the treatment of patients with type 2 diabetes mellitus and chronic kidney disease.Cardiovascular effects of gliptins.Cardiovascular effects of dipeptidyl peptidase-4 inhibitors: from risk factors to clinical outcomes.Dipeptidyl peptidase-4 inhibitors and their effects on the cardiovascular system.The role of DPP4 activity in cardiovascular districts: in vivo and in vitro evidencePotential anti-atherosclerotic effects of dipeptidyl peptidase-4 inhibitors in type 2 diabetes mellitus.The pharmacokinetic considerations and adverse effects of DPP-4 inhibitors [corrected].GLP-1R activation for the treatment of stroke: updating and future perspectives.Implications of incretin-based therapies on cardiovascular disease.A Comprehensive Review of Novel Drug-Disease Models in Diabetes Drug Development.Cardiovascular effects of anti-diabetes drugs.All-cause mortality and cardiovascular effects associated with the DPP-IV inhibitor sitagliptin compared with metformin, a retrospective cohort study on the Danish population.Phosphodiesterase III inhibition increases cAMP levels and augments the infarct size limiting effect of a DPP-4 inhibitor in mice with type-2 diabetes mellitus.DPP-4 inhibitors repress NLRP3 inflammasome and interleukin-1beta via GLP-1 receptor in macrophages through protein kinase C pathway.Saxagliptin efficacy and safety in patients with type 2 diabetes mellitus and cardiovascular disease history or cardiovascular risk factors: results of a pooled analysis of phase 3 clinical trials.Proteolytic degradation of neuropeptide Y (NPY) from head to toe: Identification of novel NPY-cleaving peptidases and potential drug interactions in CNS and Periphery.Cardiovascular safety of glucose-lowering agents as add-on medication to metformin treatment in type 2 diabetes: report from the Swedish National Diabetes Register.Efficacy and safety of saxagliptin in patients with type 2 diabetes: A systematic review and meta-analysis.
P2860
Q28081569-63A9D166-E5D9-426D-A889-EE9CEFEDF04AQ33716972-463066BA-EADB-46AC-AC01-6DC2F56A2B1DQ34062829-F7D6DF77-86FF-406D-8783-2C3ADF17268EQ34272594-DEBA4FB5-B9D1-4937-8149-5ACA0B3F3E82Q34347884-6F9B176C-D98E-46E7-B37F-D1B93D812043Q34547492-70A031F8-FDE3-4453-A88E-C93C09DF8D3FQ34658875-0F88E452-3E8E-4316-888A-3CFF8D155C73Q35675678-CFB50B49-28EC-4A5D-93B9-80F4119AF865Q36195926-5938588D-0EBF-4974-B9C6-2EC3D56E3711Q36254518-F40DDC81-D1C0-499F-9E5D-208F5EB51D4BQ36355550-92152C0C-99E8-4C16-BDDF-860D27BC0082Q36845055-00D37781-D830-40B3-A2DC-DEE5BB0A6280Q36946065-A95B2F43-920A-4D34-B99D-4834EEA66470Q37080167-69A06C4C-7607-4E56-A446-489B7671A337Q37195882-CE213986-3B05-44D3-93F0-016A7A49793DQ37562586-2AAA5D0E-2243-4AEA-9932-1BFDB77E128FQ38036778-752777FF-E265-45A4-AB25-37C2510D5271Q38072259-A263B3A6-3DDF-47BF-9171-ED5E5738C061Q38113092-0C578E5C-9D3F-4BDC-8829-9F5F52694BEEQ38118157-15C46B9C-FD74-4A4B-999E-F3F63D45BD8FQ38121545-18840258-F180-44FF-9DBC-CAE2862D2224Q38175855-FCBAB661-C469-4366-8CB8-360E313BA616Q38205588-B4CC7E01-3F9F-4800-BFB2-C2EE4F257003Q38207948-0D79AED5-A3B3-46F1-9285-DEBB13DD091EQ38264374-68F34E86-6B30-4114-B0D7-2AA4F4123427Q38707493-2B69F856-8764-498A-8613-6DA331605C62Q38857056-844AAEC0-11D0-4191-90B7-10007313450CQ46543039-0B6A7851-BF04-46B7-86D4-9354F4F62E81Q47288494-807C0E1A-2818-48D0-9F61-903B4879988CQ48254834-2384429D-4F20-4BA9-B5DA-A39829811C9AQ51339320-1E65915B-345F-47C3-B277-B9BF3C04755EQ52148357-3A339D3E-DC44-4969-86B1-FC06181A49E5Q54383946-C12EB61B-3306-434A-8A95-EF687E4B10A9Q55262447-18D1A04E-2342-4C33-93C4-E274633B7799
P2860
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Cardiovascular effects of the DPP-4 inhibitors.
@en
Cardiovascular effects of the DPP-4 inhibitors.
@nl
type
label
Cardiovascular effects of the DPP-4 inhibitors.
@en
Cardiovascular effects of the DPP-4 inhibitors.
@nl
prefLabel
Cardiovascular effects of the DPP-4 inhibitors.
@en
Cardiovascular effects of the DPP-4 inhibitors.
@nl
P2860
P356
P1476
Cardiovascular effects of the DPP-4 inhibitors.
@en
P2093
Silvio E Inzucchi
Tessey Jose
P2860
P304
P356
10.1177/1479164111436236
P407
P577
2012-02-15T00:00:00Z